Prograf
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $141,621 | 15 | 2 |
| 2017 | $2,354 | 98 | 53 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $141,583 | 13 | 98.3% |
| Food and Beverage | $1,893 | 99 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $500.00 | 1 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel-group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration | Astellas Pharma Global Development | $141,583 | 0 |
Top Doctors Receiving Payments for Prograf — Page 3
Manufacturing Companies
- Astellas Pharma Global Development $141,583
- Astellas Pharma US Inc $2,393
Product Information
- Type Drug
- Total Payments $143,975
- Total Doctors 55
- Transactions 113
About Prograf
Prograf is a drug associated with $143,975 in payments to 55 healthcare providers, recorded across 113 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2023. In 2023, $141,621 was paid across 15 transactions to 2 doctors.
The most common payment nature for Prograf is "Unspecified" ($141,583, 98.3% of total).
Prograf is associated with 1 research study, including "A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel-group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration" ($141,583).